Leerink Partners Maintains Outperform on Eli Lilly, Raises Price Target to $1232

Benzinga Newsdesk www.benzinga.com Positive 91.8%

Neg 0% Neu 0% Pos 91.8%

Leerink Partners analyst David Risinger maintains Eli Lilly (NYSE:LLY) with a Outperform and raises the price target from $1119 to $1232.